Literature DB >> 26213249

The Israeli public health response to wild poliovirus importation.

Ehud Kaliner1, Eran Kopel2, Emilia Anis3, Ella Mendelson4, Jacob Moran-Gilad5, Lester M Shulman4, Shepherd R Singer6, Yossi Manor7, Eli Somekh8, Shmuel Rishpon9, Alex Leventhal10, Lisa Rubin11, Diana Tasher8, Mira Honovich1, Larisa Moerman6, Tamy Shohat12, Ravit Bassal12, Danit Sofer7, Michael Gdalevich13, Boaz Lev10, Ronni Gamzu14, Itamar Grotto5.   

Abstract

In 2013, a silent wild poliovirus type 1 importation and sustained transmission event occurred in southern Israel. With the aim of preventing clinical poliomyelitis and ensuring virus re-elimination, the public health response to the importation event included intensification of clinical and environmental surveillance activities, enhancement of vaccine coverage, and supplemental immunisation with a bivalent oral polio vaccine against wild poliovirus types 1 and 3. A national campaign launched in August, 2013, resulted in vaccination of 943,587 children younger than 10 years (79% of the eligible target population). Expanded environmental surveillance (roughly 80% population coverage) documented a gradual disappearance of wild poliovirus type 1 in the country from September, 2013, to April, 2014. No paralytic poliomyelitis case was detected. A prompt extensive and coordinated national public health response, implemented on the basis of evidence-based decision making, successfully contained this serious importation and sustained transmission event of wild poliovirus to Israel. On April 28, 2015, WHO officially declared Israel as a polio-free country.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26213249     DOI: 10.1016/S1473-3099(15)00064-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  20 in total

1.  Using the social structure of markets as a framework for analyzing vaccination debates: The case of emergency polio vaccination.

Authors:  Yaron Connelly; Arnona Ziv; Uri Goren; Orna Tal; Giora Kaplan; Baruch Velan
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

Review 2.  Wild and vaccine-derived poliovirus circulation, and implications for polio eradication.

Authors:  P L Lopalco
Journal:  Epidemiol Infect       Date:  2016-11-21       Impact factor: 4.434

3.  Vaccine hesitancy as self-determination: an Israeli perspective.

Authors:  Baruch Velan
Journal:  Isr J Health Policy Res       Date:  2016-04-04

4.  Parental regret regarding children's vaccines-The correlation between anticipated regret, altruism, coping strategies and attitudes toward vaccines.

Authors:  Yaira Hamama-Raz; Eyal Ginossar-David; Menachem Ben-Ezra
Journal:  Isr J Health Policy Res       Date:  2016-11-07

5.  Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016.

Authors:  Merav Weil; Lester M Shulman; Sophia Heiman; Tali Stauber; Jacqueline Alfandari; Leah Weiss; Ilana Silberstein; Viki Indenbaum; Ella Mendelson; Danit Sofer
Journal:  Euro Surveill       Date:  2016-11-24

6.  Comparative epidemiology of poliovirus transmission.

Authors:  Navideh Noori; John M Drake; Pejman Rohani
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

7.  Lessons learned from the 2009-2010 H1N1 outbreak for the management of the 2013 silent polio outbreak.

Authors:  Iftach Sagy; Paula Feder-Bubis; Victor Novack; Tal Peleg-Sagy; Dan Greenberg
Journal:  BMC Infect Dis       Date:  2018-05-29       Impact factor: 3.090

8.  Would it be legally justified to impose vaccination in Israel? Examining the issue in light of the 2013 detection of polio in Israeli sewage.

Authors:  Shelly Kamin-Friedman
Journal:  Isr J Health Policy Res       Date:  2017-10-30

9.  Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.

Authors:  Rami Yaari; Ehud Kaliner; Itamar Grotto; Guy Katriel; Jacob Moran-Gilad; Danit Sofer; Ella Mendelson; Elizabeth Miller; Amit Huppert; E Anis; E Kopel; Y Manor; O Mor; L Shulman; R Singer; M Weil
Journal:  BMC Med       Date:  2016-06-23       Impact factor: 8.775

10.  The risk of type 2 oral polio vaccine use in post-cessation outbreak response.

Authors:  Kevin A McCarthy; Guillaume Chabot-Couture; Michael Famulare; Hil M Lyons; Laina D Mercer
Journal:  BMC Med       Date:  2017-10-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.